revefenacin

Also known as TD-4208

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.

In the Vinony graph

Vinony's link graph records 402 inbound references to revefenacin, and connects out to medication, asthma and digital object identifier.

It is catalogued under topics including Benzamides, Biphenyls and Bronchodilators.

Vinony links it to 10 Wikipedia language editions.

Key facts

Drug.image: Revefenacin.svg
Drug.image_class: skin-invert-image
Drug.width: 250
Drug.tradename: Yupelri
Drug.MedlinePlus: a619009
Drug.DailyMedID: Revefenacin
Drug.routes_of_administration: Inhalation
Drug.ATC_prefix: R03
Drug.ATC_suffix: BB08
Drug.legal_US: Rx-only
Drug.CAS_number: 864750-70-9
Drug.PubChem: 11753673
Drug.DrugBank: DB11855
Drug.ChemSpiderID: 9928376
Drug.UNII: G2AE2VE07O
Drug.KEGG: D10978
Drug.C: 35
Drug.H: 43

via Wikipedia infobox

Chemical data

Formula: C35H43N5O4
Molecular weight: 597.7 g/mol
IUPAC name: [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
SMILES: CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
InChIKey: FYDWDCIFZSGNBU-UHFFFAOYSA-N
XLogP: 4.1
Polar surface area: 108 Å²
H-bond donors: 2
H-bond acceptors: 6
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2018
Admin. routes: topical
Indications: chronic obstructive pulmonary disease, liver disease, kidney disease, Airway obstruction

via ChEMBL · EBI